Oliver Keown MD DIRECTOR, INTUITIVE VENTURES I met Oliver Keown MD, Director of Intuitive Ventures through Paul Grand’s Medtech Innovator ecosystem; we both served as judges in the Medtech Innovator pitch events. Intuitive launched its inaugural fund of $100M to fuel...
MedTech Pioneers – MedTech Innovator, The Largest Global MedTech Accelerator, From Inception To Scale
Paul Grand CEO, MEDTECH INNOVATOR (MTI) I have had the pleasure of serving as a judge, advisor and mentor to Medtech Innovator over the past few years and two Veranex Solutions companies, Ximedica and Experien Group, have been sponsors for the past five years. At the...
MedTech Pioneers – Genesis MedTech Group: An Ascending Leader in Emerging Market MedTech Innovation
Warren Wang, CHAIRMAN AND CHIEF EXECUTIVE OFFICER Tal Wenderow, VENTURE PARTNER Tal Wenderow and I connected at Life Science Intelligence’s Emerging Medtech Summit in May 2021. I was very interested in what the founder of Corindus had next on his career journey. Turns...
New Independent Medical Review Board for Germany
For medical device and diagnostic innovators, a planned organizational change in review boards for Germany’s Statutory Health Insurance (SHI) could lead to new opportunities for market access of their products. The Federal Ministry of Health in Germany is seeking to...
First Meeting of the Italian Regional Purchasing Centers
Italian public healthcare structures can buy medical devices only via tenders. Up to 2016, competitive pricing was the main rule for tender winners. Since then, the Price/Quality criteria can be applied in the rate of 70/70, 50/50, usually 30/70. Quality is not...
Escalated DRG Payment Model Pilot in China Expected to Pose a Genuine Threat to Innovators
As a critical element of accelerating the healthcare payment reform, the pilot of Diagnosis Related Groups (DRGs) in 30 major cities across China was officially announced in June by state administrations including National Healthcare Security Administration (the...
Possibility for Examination to be Included in the SHI Fee Scale Brings More Certainty for Reimbursement for New Diagnostics in Germany
Manufacturers can now have more certainty about the process of inclusion of a new laboratory, new human-genetic, or new tumor-genetic diagnostics in the SHI reimbursement fee scale EBM. In the past, the inclusion of new diagnostic tests in the EBM was not transparent,...
Germany Paves the Way for Reimbursement of Digital Health Care Apps
In Germany, doctors could potentially be prescribing health apps as medicines as early as 2020. This is one of the main objectives of the draft bill on the “Law for better provision through digitalization and innovation” (Digitale Versorgung Gesetz – DVG), which is...
ICER Set to Evaluate Non-Drug Products in 2020
The Boston-based Institute for Clinical and Economic Review (ICER), an independent research organization that conducts health technology assessments to examine the clinical and economic value of prescription drugs, medical tests, and other health care and health care...
Navigating the Italian HTA Process: Essentials to a Favorable Review
From November 1, 2016 to September 1, 2019, the Italian Medicines Agency, AIFA (Agenzia Italiana del Farmaco) evaluated a total of 166 Dossiers – 28 were related to orphan drugs, 56 to new active substances, 57 to extensions of indications for drugs already...